Blood & CSF Biomarker Tests For Dementia Detection
What is Blood & CSF Biomarker Analysis?
Blood serum and cerebrospinal fluid (CSF) biomarker analysis can be used in the diagnosis of Alzheimer’s disease and other dementias.
At our center we regularly monitor patients for cognitive changes that could signal the dementia, utilizing evidence-based screening tests along with detailed neuropsychological evaluation.
How Blood & CSF Biomarker Analysis Works
Blood Serum and Metabolic Testing
Doctors may send for different laboratory tests to help diagnose dementia and/or rule out other conditions, such as thyroid or vitamin deficiencies, that can contribute to symptoms.
Some examples of tests that may be requested include a complete blood count, blood glucose test, urinalysis, drug and alcohol tests (toxicology screen) and analysis of thyroid and thyroid-stimulating hormone levels. Our specialists order only the tests that are necessary and/or likely to improve the accuracy of a diagnosis.
Cerebrospinal Fluid (CSF) Biomarkers as Indicators
Experts believe that biomarkers (short for “biological markers”) offer a possible path for future Alzheimer’s disease detection.
A biomarker is something that can be measured to accurately and reproducibly indicate the presence of disease. Several potential biomarkers are being studied for their ability to indicate early stages of Alzheimer’s disease. Examples include beta-amyloid and tau levels in cerebrospinal fluid (CSF) and brain changes detectable by imaging (e.g. amyloid imaging).
Research suggests that Alzheimer’s disease in early stages may be detectable through changes in CSF levels of tau and beta-amyloid, two proteins that form abnormal brain deposits strongly linked to Alzheimer’s.
When additional insight is needed, we may include biomarker testing. For example, P-Tau217 refers specifically to tau phosphorylated at threonine 217. This epitope appears to be highly specific to Alzheimer-type tau pathology and closely tracks amyloid pathology as well.
Historically we relied on:
- CSF Aβ42, total tau, and p-tau
- Amyloid PET
Serum P-Tau217 is part of the shift toward blood-based biomarkers.
How Serum P-Tau217 Is Used Clinically
1. It reflects brain pathology
When amyloid pathology accumulates in the brain, it appears to trigger downstream tau phosphorylation. P-Tau217 rises in plasma early, often before overt dementia.
It correlates strongly with:
- Amyloid PET positivity
- CSF amyloid abnormalities
- Tau PET signal
In several studies, plasma P-Tau217 discriminates AD from non-AD neurodegenerative disorders with high accuracy, often AUC > 0.90 in research settings.
2. Diagnostic role
Serum P-Tau217 is not used alone to “diagnose Alzheimer’s” in a vacuum.
It is used in context:
Patient with cognitive complaints
- Memory-predominant profile
- Gradual onset
- Progressive course
If plasma P-Tau217 is elevated:
- High likelihood underlying AD pathology
- May reduce need for immediate PET in some settings
- Helps triage for disease-modifying therapies (e.g., anti-amyloid infusional medications)
P-Tau217 helps (among other testing) in distinguishing AD from:
Vascular dementia
Frontotemporal dementia
Dementia with Lewy bodies
Get Expert Care from Leading Specialists
For a consultation or second opinion, Call us at 310-582-7641